AU – Media & Press
Phebra Establishes New Subsidiary In Canada And Announces Marketing Approval For Its IV Arsenic Trioxide Solution
Australian pharmaceutical firm Phebra (the ‘Company’) has continued its international business expansion with the opening of its subsidiary in Montreal, Canada.
Phebra Expands Head Office
Phebra has announced a $4 million expansion of its Sydney multi-purpose sterile injectables site.
Phebra Launches New Brand of Phosphate Tablets
Phebra has launched its own brand of Phosphate 500 mg effervescent tablets to replace the discontinued Phosphate Sandoz effervescent tablets.
Phebra Announces UK Subsidiary Company
Phebra is pleased to announce the expansion of its international operations, with the establishment of new wholly-owned subsidiary company in the United Kingdom (UK).
Oral Arsenic Formulation for Treatment of Acute Promyelocytic Leukaemia (APL)
Australian pharmaceutical manufacturer Phebra, is pleased to announce its development of an innovative oral arsenic trioxide formulation for the treatment of APL.
Phebra Welcomes PBS Listing of Benzatropine Injection
Phebra is pleased that its Australian made Benzatropine Injection (benzatropine mesilate) is now accessible via the Pharmaceutical Benefits Scheme (PBS).
Phebra Welcomes PBS Listing of Narcan® Injection
Phebra has welcomed the listing of the lifesaving Narcan® Injection (naloxone hydrochloride) on the Australian Pharmaceutical Benefits Scheme (PBS).
New Study Shows Benefits of Caffeine For Pre-Term Babies
Phebra has welcomed the findings of a landmark new study which shows the sustained benefits of giving neonatal caffeine to pre-term babies suffering breathing difficulties.
Sodium Bicarbonate US Supply Agreement
Phebra has entered into a commercial agreement to supply Sodium Bicarbonate Injection to the US to assist with a shortage in the US hospital market.
Phebra Welcomes PBS Listing for Leukaemia Treatment
Phebra has welcomed the listing on the Australian PBS of its PHENASEN® (arsenic trioxide) Injection for the first line treatment of newly-diagnosed acute promyelocytic leukaemia (APL).